| Entry |
|
|---|
| Name |
Idursulfase (USAN/INN);
Idursulfase (genetical recombination) (JAN);
Elaprase (TN) |
|---|
| Product |
|
|---|
| Sequence |
SETQANSTTD ALNVLLIIVD DLRPSLGCYG DKLVRSPNID QLASHSLLFQ NAFAQQAVCA
PSRVSFLTGR RPDTTRLYDF NSYWRVHAGN FSTIPQYFKE NGYVTMSVGK VFHPGISSNH
TDDSPYSWSF PPYHPSSEKY ENTKTCRGPD GELHANLLCP VDVLDVPEGT LPDKQSTEQA
IQLLEKMKTS ASPFFLAVGY HKPHIPFRYP KEFQKLYPLE NITLAPDPEV PDGLPPVAYN
PWMDIRQRED VQALNISVPY GPIPVDFQRK IRQSYFASVS YLDTQVGRLL SALDDLQLAN
STIIAFTSDH GWALGEHGEW AKYSNFDVAT HVPLIFYVPG RTASLPEAGE KLFPYLDPFD
SASQLMEPGR QSMDLVELVS LFPTLAGLAG LQVPPRCPVP SFHVELCREG KNLLKHFRFR
DLEEDPYLPG NPRELIAYSQ YPRPSDIPQW NSDKPSLKDI KIMGYSIRTI DYRYTVWVGF
NPDEFLANFS DIHAGELYFV DSDPLQDHNM YNDSQGGDLF QLLMP |
|---|
| Type |
Peptide |
|---|
| Remark |
| Therapeutic category: | 3959 |
|
|---|
| Efficacy |
Lysosomal storage disease treatment, Enzyme replacement (iduronate-2-sulfatase) |
|---|
| Disease |
|
|---|
| Comment |
Enzyme replacement therapy product
|
|---|
| Target |
|
|---|
| Network |
| N10013 | Replacement of deficient IDS |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16AB Enzymes
A16AB09 Idursulfase
D04499 Idursulfase (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
Idursulfase
D04499 Idursulfase (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
395 Enzyme preparations
3959 Others
D04499 Idursulfase (USAN/INN); Idursulfase (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Sulfatases
IDS* [HSA_VAR:3423v1]
D04499 Idursulfase (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D04499
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D04499
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D04499
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D04499
Pharmacogenomic biomarkers [br08341.html]
Germline mutations in genetic disorder treatments
D04499
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
